MDCalc vs iatroX Calculators: Global Standards vs UK-Contextualised Clinical Tools

Featured image for MDCalc vs iatroX Calculators: Global Standards vs UK-Contextualised Clinical Tools

MDCalc is the most widely used clinical calculator platform in the world — over 600 tools, fast interface, and reliably accurate calculations. If you trained in the US or have MDCalc bookmarked from medical school, it is probably your default.

But for UK doctors, pharmacists, and ANPs, there is a jurisdiction problem. MDCalc's clinical context defaults to US guidelines — ACC/AHA for cardiovascular risk, ATS/IDSA for pneumonia management, and US dosing conventions. The calculation is correct. The interpretation references the wrong guidelines for UK practice.

Where the Jurisdiction Matters

CVD risk: MDCalc defaults to ASCVD Pooled Cohort Equations (7.5% treatment threshold per ACC/AHA). UK practice uses QRISK3 (10% threshold per NICE CG181). Different tool, different threshold, different treatment decision. iatroX QRISK3 references NICE CG181 directly.

Pneumonia: MDCalc's CURB-65 interpretation references ATS/IDSA. UK practice follows BTS/NICE — different antibiotic recommendations and admission thresholds. iatroX CURB-65 references BTS/NICE.

AF anticoagulation: MDCalc's CHA₂DS₂-VASc references ACC/AHA/HRS. UK practice follows NICE NG196 — DOACs first-line, specific exceptions. iatroX CHA₂DS₂-VASc references NICE NG196.

Comparison

FeatureMDCalciatroX Calculators
Calculator count600+80+
Clinical contextUS (ACC/AHA, ATS)UK (NICE, BNF, BTS)
Default unitsUS (mg/dL)UK (µmol/L)
NICE-referenced interpretationNoYes
Clinical pearls (UK-specific)SomeEvery calculator
Cross-linked pathwaysLimitedYes (e.g., Wells PE → sPESI → D-dimer)
AdsYesNo
FreeYes (with ads)Yes (no ads)

Who Should Use Which

Use iatroX Calculators as your primary tool for the scores you use daily in UK practice — where the guideline context directly affects the clinical decision. Use MDCalc as a secondary reference for specialist or rare calculators that iatroX does not yet cover.

Share this insight